TriangleNCT01034553 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Every 28 day cycle(up to 10 cycles) then follow-up for up to 2 years
Analysis population: All patients that received treatment were evaluated.
Groups in this outcome
All Patients
Patients receive oral aurora A kinase inhibitor MLN8237 and bortezomib IV. \> \> Aurora A kinase inhibitor MLN8237: Given orally \> \> bortezomib: Given IV
| Group | Source count |
|---|---|
| All Patients | 26 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| All Patients | 23.6 | Not reported | 17.4 | NA | Insufficient number of participants with events |
Complete source fields
- classes
- categories
- measurements
- comment
- Insufficient number of participants with events
- group Id
- OG000
- lower Limit
- 17.4
- upper Limit
- NA
- value
- 23.6
- denoms
- counts
- group Id
- OG000
- value
- 26
- units
- Participants
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive oral aurora A kinase inhibitor MLN8237 and bortezomib IV. \> \> Aurora A kinase inhibitor MLN8237: Given orally \> \> bortezomib: Given IV
- id
- OG000
- title
- All Patients
- param Type
- MEDIAN
- population Description
- All patients that received treatment were evaluated.
- reporting Status
- POSTED
- time Frame
- Every 28 day cycle(up to 10 cycles) then follow-up for up to 2 years
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice